Enhancing activity of CAR T cells by co-introducing a bispecific antibody
US11795240B2 · kind B2 · utility
1Cited by
59References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 24, 2020 |
| Grant date | Oct 24, 2023 |
| Priority date | — |
| Expiry date | May 9, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a T cell, genetically modified to express a chimeric antigen receptor (CAR), a bispecific antibody, or a combination thereof to a subject. The CAR and bispecific antibody of the invention can comprise a human antibody, a humanized antibody, or antigen-binding fragments thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.